Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China

Price
19.03 CNY
Market cap
2.90 bn CNY
P/E (2025)
21.34
P/S (2025)
5.45
Dividend yield
0.61 %
Net margin
25.53 %
Return on equity (ROE)
9.10 %
Return on assets (ROA)
8.33 %

Zhejiang Haisen Pharmaceutical Co. Ltd. A financials

Fiscal year20242025
Revenue471.51 m CNY532.26 m CNY
Gross profit195.55 m CNY242.71 m CNY
Operating income124.55 m CNY148.56 m CNY
EBIT142.16 m CNY157.10 m CNY
Net income122.56 m CNY135.88 m CNY
Diluted EPS – continuing operations0.81 CNY0.89 CNY

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Zhejiang Haisen Pharmaceutical Co. Ltd. A

Zhejiang Haisen Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients, and preparations in China and internationally. The company offers active pharmaceutical ingredients for use as antilipemic agents, antipyretic analgesics, antidepressants, analgesics, antibacterial agents, histamine drugs, and anticonvulsants, as well as for anti-gastric ulcers, and digestive and cardiovascular applications. It also provides chemical products for use as paroxetine HCl and amikacin sulphate intermediates and food additives; and escitalopram oxalate tablets to treat depression and panic disorders under the Tezi brand. In addition, the company engages in the import and export of goods; trading; and medical research and experimental development activities. Zhejiang Haisen Pharmaceutical Co., Ltd. was incorporated in 1998 and is headquartered in Dongyang, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.